Document Detail

Newborn screening for SCID: where are we now?
MedLine Citation:
PMID:  25387596     Owner:  NLM     Status:  Publisher    
Newborn screening (NBS) for severe T-cell lymphopenia/severe combined immunodeficiency using the T-cell receptor excision circle assay continues to expand in the USA and worldwide. Here, we will review why severe combined immunodeficiency is an excellent case for NBS, the outcomes of the first 6 years of screening, and dilemmas surrounding screening and management of infants detected by NBS. We will also discuss the future of NBS for primary immunodeficiencies.
Becky J Buelow; John M Routes; James W Verbsky
Related Documents :
22375256 - Early versus late parenteral nutrition in very low birthweight neonates: a retrospectiv...
22970666 - Turn and face the strange - to neonatal resuscitation guidelines in...
23181136 - Risks associated with delivering infants 2 to 6 weeks before term-a review of recent data.
20705576 - Identification of iowa live births in the agricultural health study.
18277056 - Urinary malondialdehyde levels in newborns following delivery room resuscitation.
9697716 - Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-12
Journal Detail:
Title:  Expert review of clinical immunology     Volume:  -     ISSN:  1744-8409     ISO Abbreviation:  Expert Rev Clin Immunol     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-12     Completed Date:  -     Revised Date:  2014-11-13    
Medline Journal Info:
Nlm Unique ID:  101271248     Medline TA:  Expert Rev Clin Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-9     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Four Japanese cases of dendritic cell neurofibroma with pseudorosettes.
Next Document:  Prior Authorization in the Treatment of Patients with pDPN and FM.